SPRY1 and pulmonary fibrosis: SPRY1, a direct target of miR‐21, inhibits the ERK/NF‐κB pathway in angiotensin II–induced liver fibrosis7 and bleomycin (BLM)‐induced lung fibrosis in rats.8